CLYM

Guggenheim initiated coverage of Climb Bio with a rating of Buy and set a new price target of $35.00

8-K - Climb Bio, Inc. (0001768446) (Filer)

Company to share additional CLYM116 clinical data and plans for further development at R&D Spotlight in late summer Initiation of CLYM116 dosing in IgAN patients in Mabworks Phase 2 study expected in Q3 2026 WELLESLEY HILLS, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced translational pharmacometric modeling and initial Phase 1 safety data for CLYM116, its anti-APRIL monoclonal antibody. Clinical data demonstrated a favorable initial safety profile, supporting continued development of CLYM116 in IgA nephropathy (IgAN). These data will be pres

S-3 - Climb Bio, Inc. (0001768446) (Filer)

WELLESLEY HILLS, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced upcoming presentations for its CLYM116 and budoprutug programs at the European Renal Association Congress 2026, which will be held in Glasgow, Scotland June 3-6, 2026. Climb Bio will present pharmacokinetic/pharmacodynamic modeling from nonhuman primates to humans for CLYM116, a novel ‘sweeper' anti-APRIL monoclonal antibody, which is being developed to treat IgA nephropathy (IgAN). Initial safety data from the ongoing CLYM116 Phase 1 study in healthy volunteers will also be presen

WELLESLEY HILLS, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced an upcoming presentation on its budoprutug program at the European Hematology Association (EHA) 2026 Congress, which will be held in Stockholm, Sweden June 11-14, 2026. Climb Bio will present data, including safety, B-cell depletion and initial platelet data from the low dose cohort (250mg at 24 weeks), from the ongoing Phase 1b/2a trial of budoprutug, a novel anti-CD19 monoclonal antibody, in previously treated patients with primary immune thrombocytopenia (ITP). Abstracts are av

WELLESLEY HILLS, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQFormat: Fireside ChatDate: Tuesday, May 19 Time: 11:00 – 11:30 a.m. ET Jefferies Global Healthcare Conference Format: Fireside ChatDate: Thursday, June 4 Time: 2:35 – 3:05 p.m. ET The live webcasts will be accessible via the "Investors & Media" section of the Climb Bio website. Webcast replays will be available on

10-Q - Climb Bio, Inc. (0001768446) (Filer)

8-K - Climb Bio, Inc. (0001768446) (Filer)

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development CLYM116 modeling and initial Phase 1 safety data to be presented at ERA 2026 with initial Phase 1 PK/PD data expected mid-2026 Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; anticipate data from all ongoing trials in 2026 Secured $110 million private placement led by top-tier healthcare investors WELLESLEY HILLS, Mass., May 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarter

8-K - Climb Bio, Inc. (0001768446) (Filer)

Chardan Capital Markets initiated coverage of Climb Bio with a rating of Buy and set a new price target of $22.00

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued development Budoprutug pMN, ITP, and SLE clinical trials enrolling to plan; Fast Track Designation received for pMN Initial data from ITP trial anticipated in June; initial data from pMN and SLE trials anticipated Q4 2026 Company to host R&D Spotlight Webcast today, May 5, 2026 WELLESLEY HILLS, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced progress updates for budoprutug, the Company's anti-CD19 monoclonal antibody. The Company is hosting

D - Climb Bio, Inc. (0001768446) (Filer)

4 - Climb Bio, Inc. (0001768446) (Issuer)

SCHEDULE 13D/A - Climb Bio, Inc. (0001768446) (Subject)

8-K - Climb Bio, Inc. (0001768446) (Filer)

WELLESLEY HILLS, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell securities in a private placement for aggregate gross proceeds of approximately $110.0 million, before deducting placement agent fees and other offering expenses. The private placement is expected to close on or about April 29, 2026, subject to the satisfaction of customary closing conditions. The private placement included participation from new and existing shareholders

DEFA14A - Climb Bio, Inc. (0001768446) (Filer)

DEF 14A - Climb Bio, Inc. (0001768446) (Filer)

Mizuho initiated coverage of Climb Bio with a rating of Outperform and set a new price target of $18.00

PRE 14A - Climb Bio, Inc. (0001768446) (Filer)

WELLESLEY HILLS, Mass., April 08, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight Series - a budoprutug webcast event, which is set for Tuesday, May 5, 2026, at 8:00 a.m. ET. The event will highlight the Company's budoprutug program, a clinical-stage, anti-CD19 monoclonal antibody with the potential to address a broad range of B-cell mediated, immune-driven diseases. Budoprutug is being evaluated in clinical trials for primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus

WELLESLEY HILLS, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to budoprutug, the company's investigational anti-CD19 monoclonal antibody, for the treatment of primary membranous nephropathy (pMN)—a rare kidney disease for which there are currently no FDA-approved treatments. "Fast Track Designation recognizes both the urgent need for new therapies in pMN and the compelling early clinical activity generated to date with budoprutug," said Edgar Charles, M.D.,

8-K - Climb Bio, Inc. (0001768446) (Filer)